299 related articles for article (PubMed ID: 16368268)
1. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.
Marino MJ; Conn PJ
Curr Opin Pharmacol; 2006 Feb; 6(1):98-102. PubMed ID: 16368268
[TBL] [Abstract][Full Text] [Related]
2. Ionotropic and metabotropic glutamate receptor structure and pharmacology.
Kew JN; Kemp JA
Psychopharmacology (Berl); 2005 Apr; 179(1):4-29. PubMed ID: 15731895
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in positive allosteric modulators of metabotropic glutamate receptors.
Shipe WD; Wolkenberg SE; Williams DL; Lindsley CW
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):449-57. PubMed ID: 16022181
[TBL] [Abstract][Full Text] [Related]
4. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors.
Hemstapat K; Da Costa H; Nong Y; Brady AE; Luo Q; Niswender CM; Tamagnan GD; Conn PJ
J Pharmacol Exp Ther; 2007 Jul; 322(1):254-64. PubMed ID: 17416742
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptor ligands as potential therapeutics for addiction.
Olive MF
Curr Drug Abuse Rev; 2009 Jan; 2(1):83-98. PubMed ID: 19630739
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
7. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.
Ritzén A; Mathiesen JM; Thomsen C
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):202-13. PubMed ID: 16176554
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease.
Benarroch EE
Neurology; 2008 Mar; 70(12):964-8. PubMed ID: 18347319
[No Abstract] [Full Text] [Related]
9. mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.
East SP; Gerlach K
Expert Opin Ther Pat; 2010 Mar; 20(3):441-5. PubMed ID: 20180624
[TBL] [Abstract][Full Text] [Related]
10. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
O'Brien JA; Lemaire W; Chen TB; Chang RS; Jacobson MA; Ha SN; Lindsley CW; Schaffhauser HJ; Sur C; Pettibone DJ; Conn PJ; Williams DL
Mol Pharmacol; 2003 Sep; 64(3):731-40. PubMed ID: 12920211
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
Lindsley CW; Hopkins CR
Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
[TBL] [Abstract][Full Text] [Related]
12. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders.
Spooren WP; Gasparini F; Salt TE; Kuhn R
Trends Pharmacol Sci; 2001 Jul; 22(7):331-7. PubMed ID: 11431019
[TBL] [Abstract][Full Text] [Related]
13. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.
Le Poul E; Boléa C; Girard F; Poli S; Charvin D; Campo B; Bortoli J; Bessif A; Luo B; Koser AJ; Hodge LM; Smith KM; DiLella AG; Liverton N; Hess F; Browne SE; Reynolds IJ
J Pharmacol Exp Ther; 2012 Oct; 343(1):167-77. PubMed ID: 22787118
[TBL] [Abstract][Full Text] [Related]
14. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
Koltunowska D; Gibula-Bruzda E; Kotlinska JH
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():242-9. PubMed ID: 23623810
[TBL] [Abstract][Full Text] [Related]
15. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
[TBL] [Abstract][Full Text] [Related]
16. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.
Vernon AC; Croucher MJ; Dexter DT
Neuroreport; 2008 Mar; 19(4):475-8. PubMed ID: 18287950
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
[TBL] [Abstract][Full Text] [Related]
18. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
[TBL] [Abstract][Full Text] [Related]
19. Positive and negative modulation of circadian activity rhythms by mGluR5 and mGluR2/3 metabotropic glutamate receptors.
Gannon RL; Millan MJ
Neuropharmacology; 2011; 60(2-3):209-15. PubMed ID: 20831878
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor.
Cid JM; Duvey G; Cluzeau P; Nhem V; Macary K; Raux A; Poirier N; Muller J; Boléa C; Finn T; Poli S; Epping-Jordan M; Chamelot E; Derouet F; Girard F; Macdonald GJ; Vega JA; de Lucas AI; Matesanz E; Lavreysen H; Linares ML; Oehlrich D; Oyarzábal J; Tresadern G; Trabanco AA; Andrés JI; Le Poul E; Imogai H; Lutjens R; Rocher JP
ACS Chem Neurosci; 2010 Dec; 1(12):788-95. PubMed ID: 22778815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
